

New Alzheimer's Biomarker May Facilitate Rapid Diagnosis

Discovery of a unique ratio of metabolites from blood samples of early-stage Alzheimer's patients promises to speed diagnosis, allowing for earlier treatments.

JACKSON, WYOMING, UNITED STATES OF AMERICA, April 21, 2022


/EINPresswire.com/ -- Although symptoms of advanced Alzheimer's disease are well known, diagnosis of Alzheimer's disease in its earliest stages requires careful cognitive testing by neurologists.

Discovery of a unique ratio of metabolites from blood samples of early-stage Alzheimer's patients promises to speed diagnosis, allowing earlier treatments to be initiated.

"We were delighted to discover that the ratio of two molecules, 2-aminoethyl dihydrogen phosphate and taurine, allows us to reliably discriminate samples of early-stage Alzheimer's patients from controls," said Dr. Sandra Banack, lead author of the report in PLOS ONE and Senior Scientist at the [Brain Chemistry Labs](#) in Jackson Hole.

The blood samples were drawn from patients enrolled in an FDA-approved Phase II trial at Dartmouth Hitchcock Medical Center in New Hampshire and then shipped to the Brain Chemistry Labs for analysis.

Current attempts to diagnose Alzheimer's disease from blood samples depend on the presence of amyloid fragments, the molecules that cause brain tangles and plaques. "At the Brain Chemistry Labs, we consider amyloid plaques to be a consequence rather than the cause of Alzheimer's disease," Dr. Paul Alan Cox, Executive Director of the Brain Chemistry Labs explains. "What is exciting about this new discovery is that it does not depend on amyloid and the assay can be performed on analytical equipment that is already present in most large hospitals."



Dr. Sandra Banack Analyzing Alzheimer's Blood Samples at the Brain Chemistry Labs in Jackson Hole.
© 2022 Paul Alan Cox

Their report, written with Alzheimer's expert Dr. Aleksandra Stark, "A Possible Blood Plasma Biomarker for Early-stage Alzheimer's Disease" is being published this week in PLOS ONE.

Link to the article: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267407>

#

About the Brain Chemistry Labs: The Brain Chemistry Labs is a not-for-profit research institute based in Jackson Hole focused on improving outcomes for patients suffering from Alzheimer's, ALS, and other neurodegenerative illnesses.

Contacts:

Dr. Sandra Banack, Tel: 307-734-1680, sandra@ethnomedicine.org

Dr. Paul Alan Cox, Tel: 801-375-6214, paul@ethnomedicine.org

Paul Alan Cox, Ph.D.

Brain Chemistry Labs

+1 801-375-6214

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/569040064>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.